Antifungal Susceptibility Testing

Infectious Disease Clinics of North America

Volumn 20, Issue 3, 2006, Pages 699-709

  Fothergill, Annette W ^a   Rinaldi, Michael G ^a,b   Sutton, Deanna A ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b Clinical Microbiology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; PYRROLE DERIVATIVE; RIFAMPICIN; TERBINAFINE; VORICONAZOLE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ASPERGILLUS; BLASTOMYCES DERMATITIDIS; CANDIDA; COCCIDIOIDES IMMITIS; COMBINATION TESTING; CORRELATION ANALYSIS; FUNGUS; FUSARIUM; HISTOPLASMA CAPSULATUM; HUMAN; LABORATORY AUTOMATION; MEDICAL DECISION MAKING; MICROTITER PLATE ASSAY; MINIMUM INHIBITORY CONCENTRATION; MOLD TESTING; MOULD; MYCOSIS; NONHUMAN; PAECILOMYCES; PATIENT CARE; REVIEW; RHIZOPUS; SCEDOSPORIUM; SPOROTHRIX; STANDARD; YEAST;

ANTIFUNGAL AGENTS; DRUG RESISTANCE, FUNGAL; FUNGI; HUMANS; LABORATORIES; MICROBIAL SENSITIVITY TESTS;

EID: 33748696201     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.idc.2006.06.008     Document Type: Review

References (22)

1. NCCLS. Reference method for broth dilution antifungal susceptibility testing of yeasts; proposed standard NCCLS document M27-P (1992), National Committee for Clinical Laboratory Standards, Wayne (PA)
2. NCCLS. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard NCCLS document M27-A2 (2002), National Committee for Clinical Laboratory Standards, Wayne (PA)
3. Espinel-Ingroff A., Barchiesi F., Cuenca-Estrella M., et al. International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp to fluconazole, itraconazole, posaconazole, and voriconazole. J Clin Microbiol 43 8 (2005) 3884-3889
4. NCCLS. Reference method for broth dilution antifungal susceptibility testing of conidial-forming filamentous fungi; approved standard NCCLS M38-A (2002), National Committee for Clinical Laboratory Standards, Wayne (PA)
5. NCCLS. Reference method for antifungal disk diffusion susceptibility testing of yeasts; approved guideline NCCLS document M44-A (2004), National Committee for Clinical Laboratory Standards, Wayne (PA)
6. Barry A., Bille J., Brown S., et al. Quality control limits from fluconazole disk susceptibility tests on Mueller-Hinton agar with glucose and methylene blue. J Clin Microbiol 41 7 (2003) 3410-3412
7. Espinel-Ingroff A., Pfaller M., Messer S.A., et al. Multicenter comparison of the Sensititre YeastOne colorimetric antifungal panel with the NCCLS M27-A2 reference methods for testing new antifungal agents against clinical isolates of Candida spp. J Clin Microbiol 42 2 (2004) 718-721
8. Maxwell M.J., Messer S.A., Hollis R.J., et al. Evaluation of ETEST method for determining fluconazole and voriconazole MICs for 279 clinical isolates of Candida species infrequently isolated from blood. J Clin Microbiol 41 3 (2003) 1087-1090
9. Maxwell M.J., Messer S.A., Hollis R.J., et al. Evaluation of ETEST method for determining voriconazole and amphotericin B MICs for 162 clinical isolates of Cryptococcus neoformans. J Clin Microbiol 41 1 (2003) 97-99
10. Rex J.H., and Pfaller M.A. Has antifungal susceptibility testing come of age?. Clin Infect Dis 35 8 (2002) 982-989
11. Chaturvedi V., Ramani R., and Rex J.H. Collaborative study of antibiotic medium 3 and flow cytometry for identification of amphotericin B-resistant Candida isolates. J Clin Microbiol 42 5 (2004) 2252-2254
12. Pappagianis D., Collins M.S., Hector R., et al. Development of resistance to amphotericin B in Candida lusitaniae infecting a human. Antimicrob Agents Chemother 16 (1979) 123-126
13. Merz W.G. Candida lusitaniae: frequency of recovery, colonization, infection, and amphotericin B resistance. J Clin Microbiol 20 (1984) 1194-1195
14. Pfaller M.A., Messer S.A., Hollis R.J., et al. Trends in species distribution and susceptibility to fluconazole among blood stream isolates of Candida species in the United States. Diagn Microbiol Infect Dis 33 (1999) 217-222
15. Messer S.A., Diekema D.J., Boyken L., et al. Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp. J Clin Microbiol 44 2 (2006) 324-326
16. Odds F.C., Motyl M., Andrade R., et al. Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. J Clin Microbiol 42 8 (2004) 3475-3482
17. Pfaller M.A., Boyken L., Hollis R.J., et al. In vitro susceptibilities of Candida spp to caspofungin; four years of global surveillance. J Clin Microbiol 44 3 (2006) 760-763
18. Pfaller M.A., Boyken L., Hollis R.J., et al. In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp, including 315 isolates resistant to fluconazole. J Clin Microbiol 43 11 (2005) 5424-5427
19. Pfaller M.A., Diekema D.J., Boyken L., et al. Effectiveness of anidulafungin in eradicating Candida species in invasive candidiasis. Antimicrob Agents Chemother 49 11 (2005) 4795-4797
20. Lewis R.E., and Kontoyiannis D.P. Rationale for combination antifungal therapy. Pharmacotherapy 21 8 Pt 2 (2001) 149S-164S
21. Johnson M.D., MacDougal C., Ostrosky-Zeichner L., et al. Mini review: combination antifungal therapy. Antimicrob Agents Chemother 48 3 (2004) 693-715
22. Greco W.R., Bravo G., and Parsons J.C. The search for synergy; a critical review from a response surface perspective. Pharmacol Rev 47 (1995) 331-385